Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands
暂无分享,去创建一个
Raquel Hontecillas | Josep Bassaganya-Riera | David R. Bevan | Stephanie N. Lewis | Zulma Garcia | J. Bassaganya-Riera | R. Hontecillas | D. Bevan | S. Lewis | Zulma Garcia
[1] Tudor I. Oprea,et al. Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..
[2] Armin Ruf,et al. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .
[3] D. Zalko,et al. Characterization of Novel Ligands of ER{alpha}, Er{beta}, and PPAR{gamma}: The Case of Halogenated Bisphenol A and Their Conjugated Metabolites. , 2011 .
[4] Michael M. Mysinger,et al. Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.
[5] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[6] J. Berger,et al. The Differential Interactions of Peroxisome Proliferator-Activated Receptor γ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities , 2008, Molecular Pharmacology.
[7] Sudipto Mukherjee,et al. Evaluation of DOCK 6 as a pose generation and database enrichment tool , 2012, Journal of Computer-Aided Molecular Design.
[8] Klaus R. Liedl,et al. Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation , 2012, PloS one.
[9] K. Morikawa,et al. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. , 2009, Journal of molecular biology.
[10] W. Bilker,et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.
[11] E. Novellino,et al. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. , 2008, Journal of medicinal chemistry.
[12] S. Nissen,et al. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.
[13] W. Wahli. A gut feeling of the PXR, PPAR and NF‐κB connection , 2008, Journal of internal medicine.
[14] B. Spiegelman,et al. PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.
[15] Larry Wall,et al. Learning Perl , 1993 .
[16] J. Pin,et al. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.
[17] Scott A. Busby,et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.
[18] A. Billin,et al. The next generation of PPAR drugs: do we have the tools to find them? , 2007, Biochimica et biophysica acta.
[19] J. Ellenberg,et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. , 2008, Gastroenterology.
[20] Karsten Kristiansen,et al. Pharmacophore-driven identification of PPARγ agonists from natural sources , 2011, J. Comput. Aided Mol. Des..
[21] P. Chavatte,et al. Structural Insight into PPAR? Ligands Binding , 2009 .
[22] J. Irwin,et al. Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.
[23] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Bassaganya-Riera,et al. Virtual Screening as a Technique for PPAR Modulator Discovery , 2009, PPAR research.
[25] J. Schwabe,et al. Structural Basis for the Activation of Pparg by Oxidised Fatty Acids , 2008 .
[26] J. Henney. Infant Pneumococcal Vaccine , 2000 .
[27] Xiaohua Zhang,et al. Message passing interface and multithreading hybrid for parallel molecular docking of large databases on petascale high performance computing machines , 2013, J. Comput. Chem..
[28] Olivier Michielin,et al. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. , 2007, Biochimica et biophysica acta.
[29] B. Spiegelman,et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. , 2002, Genes & development.
[30] Claudio N. Cavasotto,et al. Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.
[31] M. Lindstrom,et al. T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor γ Binding Properties* , 2008, Journal of Biological Chemistry.
[32] E. Novellino,et al. Insights into the Mechanism of Partial Agonism , 2007, Journal of Biological Chemistry.
[33] A. Moss,et al. Balsalazide disodium for the treatment of ulcerative colitis , 2008, Expert review of gastroenterology & hepatology.
[34] L. Higgins,et al. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. , 2010, The American journal of clinical nutrition.
[35] D. Zalko,et al. Characterization of novel ligands of ERα, Erβ, and PPARγ: the case of halogenated bisphenol A and their conjugated metabolites. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[36] J. Kazius,et al. Derivation and validation of toxicophores for mutagenicity prediction. , 2005, Journal of medicinal chemistry.
[37] D. Goodsell,et al. Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.
[38] Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. , 2009 .
[39] H. Xu,et al. Structure-based design of potent retinoid X receptor alpha agonists. , 2004, Journal of medicinal chemistry.
[40] S. Paliwal,et al. In silico structure-based drug design approach to develop novel pharmacophore model of human peroxisome proliferator-activated receptor γ agonists , 2011, Medicinal Chemistry Research.
[41] Hairong Zhou,et al. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. , 2008, Bioorganic & medicinal chemistry.
[42] Y. Hashimoto,et al. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures , 2009, Acta crystallographica. Section D, Biological crystallography.
[43] Yoshitomo Hamuro,et al. Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.
[44] I-Lin Lu,et al. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. , 2005, Journal of medicinal chemistry.
[45] M. Lazar,et al. Interdomain communication regulating ligand binding by PPAR-γ , 1998, Nature.
[46] Raquel Hontecillas,et al. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. , 2006, Clinical nutrition.
[47] Kenji Wakabayashi,et al. Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, Cerco-A. , 2011, Biological & pharmaceutical bulletin.
[48] Samy Suissa,et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.
[49] Yang Li,et al. Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma. , 2009, Bioorganic & medicinal chemistry letters.
[50] Yong Li,et al. Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[51] Millard H. Lambert,et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.
[52] Shenghua Shi,et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.
[53] Jeff T Roesgen,et al. Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. , 2006, Bioorganic & medicinal chemistry letters.
[54] Keun Woo Lee,et al. Pharmacophore Identification for Peroxisome Proliferator-Activated Receptor Gamma Agonists , 2011 .
[55] Igor Polikarpov,et al. Ajulemic Acid, a Synthetic Nonpsychoactive Cannabinoid Acid, Bound to the Ligand Binding Domain of the Human Peroxisome Proliferator-activated Receptor γ* , 2007, Journal of Biological Chemistry.
[56] E. Novellino,et al. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists. , 2012, Bioorganic & medicinal chemistry.
[57] Ruth Nussinov,et al. PharmaGist: a webserver for ligand-based pharmacophore detection , 2008, Nucleic Acids Res..
[58] V. Maltarollo,et al. Ligand‐ and Structure‐Based Drug Design Strategies and PPARδ/α Selectivity , 2012, Chemical biology & drug design.
[59] Shuichi Hirono,et al. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship. , 2011, Journal of medicinal chemistry.
[60] C. Glass,et al. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. , 2007, Trends in immunology.
[61] H. Xu,et al. Structural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor γ to PGC-1α* , 2008, Journal of Biological Chemistry.
[62] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[63] T. Willson,et al. Co-crystal structure guided array synthesis of PPARγ inverse agonists , 2007 .
[64] R. Rajapakse,et al. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis , 2009, Expert opinion on drug metabolism & toxicology.
[65] K. Wakabayashi,et al. Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives. , 2010, Bioorganic & medicinal chemistry letters.
[66] M. Lindstrom,et al. INT131: A Selective Modulator of PPARγ , 2009 .
[67] L. Jendeberg,et al. A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.
[68] J. Bassaganya-Riera,et al. F4/80hiCCR2hi macrophage infiltration into the intra-abdominal fat worsens the severity of experimental IBD in obese mice with DSS colitis , 2009 .
[69] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[70] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[71] Igor V. Tetko,et al. ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse Reactions , 2012, J. Chem. Inf. Model..
[72] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[73] J. Bassaganya-Riera,et al. PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. , 2009, Cellular immunology.
[74] E. Novellino,et al. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. , 2009, Journal of medicinal chemistry.
[75] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[76] Jürgen Bajorath,et al. New methodologies for ligand-based virtual screening. , 2005, Current pharmaceutical design.
[77] Thierry Langer,et al. Pharmacophore modeling and parallel screening for PPAR ligands , 2007, J. Comput. Aided Mol. Des..
[78] J. Bassaganya-Riera,et al. Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition. , 2006, Clinical nutrition.
[79] Peter Tontonoz,et al. Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.
[80] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[81] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[82] P. Lakatos. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.
[83] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[84] I. Lu,et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.
[85] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[86] D. Zalko,et al. Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A , 2011, Environmental health perspectives.
[87] J. S. Cohen,et al. Risks of troglitazone apparent before approval in USA , 2006, Diabetologia.
[88] Development of a complex scintillation proximity assay for high throughput screening of PPARγ modulators , 2005, Acta Pharmacologica Sinica.
[89] J. Bassaganya-Riera,et al. Dietary α-Eleostearic Acid Ameliorates Experimental Inflammatory Bowel Disease in Mice by Activating Peroxisome Proliferator-Activated Receptor-γ , 2011, PloS one.
[90] J. Holder,et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. , 1998, The Journal of pharmacology and experimental therapeutics.
[91] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[92] Mohane Selvaraj Coumar,et al. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. , 2009, Journal of medicinal chemistry.
[93] Gisbert Schneider,et al. Structure‐Based Pharmacophore Screening for Natural‐Product‐Derived PPARγ Agonists , 2009, Chembiochem : a European journal of chemical biology.
[94] Warszawski Uniwersytet Medyczny,et al. Diabetes care , 2019, Health at a Glance.
[95] J. Lehmann,et al. Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.
[96] Jerry T. Thompson,et al. Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays. , 2003, Bioorganic & medicinal chemistry.
[97] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[98] K. Morikawa,et al. The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.
[99] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[100] J. Feige,et al. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. , 2007, Biochimica et biophysica acta.
[101] T. H. Huang,et al. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. , 2009, Pharmacological research.